Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Developme
资讯
2024-10-21
The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat bra...